FOLFOX与TCF方案治疗晚期胃癌的临床观察

The Efficacy of FOLFOX and TCF Regimen in the Treatment of Patients with Advanced Gastric Cancer

目的观察比较FOLFOX方案与TCF方案治疗晚期胃癌的疗效、毒副反应。方法85例晚期胃癌随机分为FOLFOX组与TCF组。两组均以28 d为1周期,重复3个周期。近期疗效及毒副反应按WHO标准进行评价。结果FOLFOX组患者总有效率、初治有效率、Karnofsky评分改善率、中位肿瘤进展时间、中位生存期分别是48.84%、56.67%、72.09%、6.5个月、11.5个月,TCF组则分别是30.95%、35.48%、38.09%,5.5个月、9.7个月,两组有效率与中位生存期比较差异有统计学意义(P<0.05)。两组主要毒副反应为骨髓抑制、胃肠道反应、神经毒性。结论FOLFOX方案治疗晚期胃癌安全、有效,优于TCF方案。

Objective To compare the effect and toxicity between FOLFOX regimen and TCF regimen in patients with advanced gastric cancer. Methods Eighty-five patients with advanced gastric cancer were randomly divided into FOLFOX group and TCF group, both regimens were repeated every 28 days for three cycles. Objective tumor response and toxicity reactions were assessed by WHO criteria. Results The overall response rate, the first treatment response rate, the Karnofsky improvement rate, medium time to tumor progress and medium survival time were 48.84% , 56.67% , 72.09%, 6.5 months, 11.5 months in the group FOLFOX , and 30.95%, 35.48% , 38.09%,5.5 months, 9.7 months in the group TCF. There was significant difference in the response rate and medium survival time between the two groups （P 〈 0.05 ）. There were two major toxicity reactions to bone marrow suppression, gastrointestinal reactions, and neurological toxicity. Conclusions IFOLFOX regimen may be safe and effective for advanced gastric cancer and superior to TCF regimen.